脑胶质瘤替尼泊甙动脉超选择灌注及司莫司汀口服化疗

目的观察脑胶质瘤替尼泊甙动脉（VM_(26)）及口服司莫司汀（MeCCNU）化疗的疗效。方法对68例肿瘤切除手术后的脑胶质瘤病人行VM_(26)动脉超选择灌注及MeCCNU口服化疗，每间隔6－8周为一疗程，首次化疗后6个月将计算机体层摄影（CT）或磁共振成像（MRI）显示的肿瘤体积变化及临床症状评价与化疗前相比较。结果本组68例病人治疗后完全缓解9例（13．2％），部分缓解27例（39．8％），稳定19例（27．9％），恶化11例（16．2％，早期死亡（2．9％）。本组病例1年存活率89．7％，2年72．1％，3年以上存活率22．1％。全部病人无严重并发症及毒性反应。结论对手术切除的胶质瘤病人采用MeCCNU联合化疗，有益于提高胶质瘤病人的生存质量。

Superselective intrarterial infusioning VM26 and oral using MeCCNU for treatment of brain glioma

Objective To investigate the effect of superselective intraarterial infusioning VM_(26) and oral using MeCCNUchemotherapy in treating brain glioma. Method 68 postoperative patients with brain glioma were included in the study, every 6to 8 weeks was kept as a course of treatment.The size and volume of tumor mass were compared before and afer thechemotherapy 6 first months. Result In these 68 cases, 9 cases (13.2%) presented complete response; 27 cases (39.8%) partialresponse;19 cases (27.9%) no change; 11 cases (16.2%) presented depravative, 2 cases (2.9%) died in eary stage.The survivalrate of one-year,two-year and three-year in this guup were 89.7%, 72.1% and 22.1%, respectively. All the patients had nosevere complications and toxical reactions. Conclusion VM_(26)-MeCCNU combined chemotherapeutical protocol shows good short-term effect. Successive chemotherapy may improve the life quality patient with brain glioma.